Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

MDR - TB FACTS AND CONCERNS

1,397 views

Published on

MDR - TB FACTS AND CONCERNS

Published in: Health & Medicine
  • Be the first to comment

MDR - TB FACTS AND CONCERNS

  1. 1. MDR - TB FACTS AND CONCERNS Dr.T.V.Rao MD 3/23/2016Dr.T.V.Rao MD 1
  2. 2. TUBERCULOSIS IS A IMPORTANT COMMUNICABLE DISEASE, POVERTY AND POOR LIVING CONDITION INCREASE THE SPREAD OF DISEASE
  3. 3. DRUG RESISTANCE A CONCERN TO THE HUMAN RACE IN TUBERCULOSIS Anti-TB medicines have been used for decades, and resistance to them is widespread. TB strains may be resistant to one or more medicines.
  4. 4. RIFAMPICIN-RESISTANT TUBERCULOSIS (RR-TB) IS Rifampicin-resistant tuberculosis (RR-TB) is caused by TB bacteria that do not respond to rifampicin, one of the most effective anti-TB medicines, requiring longer treatment and more medication than patients with rifampicin-susceptible disease
  5. 5. MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB) IS Multidrug-resistant tuberculosis (MDR- TB) is a form of rifampicin-resistant TB that has additional resistance to isoniazid, another valuable anti-TB
  6. 6. EXTENSIVELY DRUG- RESISTANT TB (XDR-TB), Extensively drug- resistant TB (XDR-TB), is a form of multidrug- resistant tuberculosis that responds to even fewer available medicines, including the two most effective classes of “second-line” anti-TB medicines.
  7. 7. GLOBAL BURDEN IN 2014 Globally, 5% of TB cases were estimated to have had multidrug-resistant TB (MDR-TB) in 2014. Drug resistance surveillance data show that an estimated 480 000 people developed MDR-TB in 2014 and 190 000 people died as a result of MDR-TB.
  8. 8. XDR-TB Extensively drug- resistant TB (XDR- TB) has been reported by 105 countries in 2014. On average, an estimated 9.7% of people with MDR- TB have XDR-TB.
  9. 9. DETECTION OF MDR-TB PATIENTSIf all notified TB patients (6.3 million) had been tested for drug resistance in 2014, an estimated 300 000 cases of MDR-TB would have been detected. In 2014, 123 000 patients with MDR-TB or rifampicin resistant tuberculosis (RR-TB) were notified, of whom about 75%
  10. 10. DRUG SUSCEPTIBILITY TESTING More TB patients were reported to have been tested for drug resistance in 2014 than in any other year before. Worldwide, 58% of previously treated patients and 12% of new cases were tested, up from 17% and 8.5% respectively in 2013. This improvement is partly due to the adoption of rapid molecular tests and improved reporting from laboratories.
  11. 11. MDR-TB TREATMENT A total of 110 000 patients were enrolled on MDR-TB treatment in 2014, an increase of 14% compared with 2013. The ratio of enrolled to notified MDR/RR- TB cases was 90% globally, and >90% in 15 high MDR-TB burden countries as well as the European Region and the Region of Americas
  12. 12. TREATMENT OUTCOMES  Only 50% of the MDR-TB patients in the 2012 cohort of detected cases were successfully treated. 16% died, 24% did not have their treatment outcome documented or interrupted treatment, and in 10% the treatment failed. Only 26% of XDR-TB patients in the 2012 cohort had a successful outcome of treatment.
  13. 13. TRENDS An analysis of trends focusing on the years 2008−2014 shows that, at the global level, the proportion of new cases with MDR-TB remains unchanged at around 3.3%. However, serious epidemics of drug-resistant TB jeopardise TB control in several countries.
  14. 14. FIVE PRIORITY ACTIONS TO ADDRESS THE GLOBAL MDR-TB CRISIS
  15. 15. WHAT WHO THINKS ABOUT THE MDR –TB  The WHO has recently reported that there is a global failure to prevent the spread of multidrug-resistant tuberculosis (MDR-TB), which affects an estimated three million people not receiving treatment due to living in distant rural areas in developing nations. In fact, more than 95 percent of tuberculosis deaths occur in poor countries, and it is the second greatest killer worldwide after HIV/AIDS.
  16. 16. PRIORITY ONE PREVENT MDR-TB AS A FIRST PRIORITY PREVENT THE DEVELOPMENT OF DRUG RESISTANCE THROUGH HIGH QUALITY TREATMENT OF DRUG- SUSCEPTIBLE TB
  17. 17. PRIORITY TWO SCALE UP RAPID TESTING AND DETECTION OF ALL MDR/RR-TB CASES EXPAND RAPID TESTING AND DETECTION OF DRUG- RESISTANT TB CASES
  18. 18. PRIORITY THREE PROVIDE IMMEDIATE ACCESS TO EFFECTIVE TREATMENT AND PROPER CARE Ensure prompt access to appropriate MDR- TB care, including adequate supplies of quality drugs and scaled-up country capacity to deliver services
  19. 19. PRIORITY FOUR PREVENT TRANSMISSION THROUGH INFECTION CONTROL Implement appropriate TB infection control measures and quickly enrol diagnosed patients on effective treatment to minimize the risk of disease transmission
  20. 20. BEST WAY TO PREVENT TB STOP SPREADING
  21. 21. PRIORITY FIVE INCREASE POLITICAL COMMITMENT WITH FINANCING Underpin and sustain the MDR-TB response through high-level political commitment, strong leadership across multiple governmental sectors, ever-broadening partnerships, and adequate financing for care and research.
  22. 22. THINK TB, PREVENT TB, DIAGNOSE TB TREAT TB ELIMINATE TB
  23. 23. PREVENTION AND EDUCATION ON TUBERCULOSIS IS EVERYBODY'S BUSINESS Another day of Academic interaction at SDUMC KOLAR CELEBRATING TUBERCULOSIS Update and felicitating Dr Alladi Mohan from SVIMS TIRUPATHI AND EMINENT DOCTOR,SCIENTIST AN AUTHOUR AND EDITOR OF CHEST A author of greater text book on Tuberculosis seen along with HOD of Medicine Dr Prabhakar from SDUMC Kolar bringing many learned on to share views A DAY TO LEARN MANY NEW DEVELOPING TRENDS ON TUBERCULOSIS Dr T V Rao MD
  24. 24. FELICITATING A PERSON WITH GREAT MISSION TO EDUCATE AND PREVENT TUBERCULOSIS DR. ALLADI MOHAN A DOYEN IN MEDICINE AT SDUMC KOLAR KARNATAKA
  25. 25. LET US BE UNITED TO CREATE HOPE TO MANY LIVING WITH TUBERCULOSIS
  26. 26. REFERENCES WHO FACTS AND CONCERNS ON MDR – TB CDC TRENDS ON MDR- TUBERCULOIS Thanks to Department of Medicine, Management of SDUMC A Deemed to be University Kolar Karnataka India
  27. 27. ATTENTION OF VIEWERS I am thankful to many in the world who made me to achieve my desired goals faster than I thought, having > 3-5 million health professionals share and utilize my knowledge for the benefit of mankind, Today I wish to be freelancer to the world to create interest in Medical, Clinical and Diagnostic Microbiology with more emphasis on Infectious diseases and Hospital associated Infection wish to be your partner in educating many millions who know well the importance of Infectious diseases  You can visit many web sites of mine  www.medmicrobes.com  www.slidehsare.com  www.authourstream.com  www,scribd.com  Be a friend on Facebook with tummalapalli venkateswararao access  Rao’s Microbiology  Rao’s Infection care  Microbiology connected Travancore Medical College  For any assistance on INFECTION REALTED ISSUES CONTACT ME AT doctortvrao@gmail.com Mob +91 7204113154 3/23/2016Dr.T.V.Rao MD 32
  28. 28. Program Created by Dr.T.V.Rao MD for Benefit of Medical and Paramedical Professionals in the Developing World Created from World Wide Resources Email doctortvrao@gmail.com 3/23/2016Dr.T.V.Rao MD 33

×